The prostate: an increasing medical problem. The Prostate, pp.39-48, 1990. ,
Molecular and cellular pathogenesis of benign prostatic hyperplasia. The Journal of urology, pp.1784-1791, 2004. ,
Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? European urology, pp.1202-1216, 2007. ,
Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. The Prostate, pp.1774-1780, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00440934
Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial, The Prostate, vol.95, issue.4, pp.1303-1311, 2009. ,
DOI : 10.1002/pros.20974
Inflammation of the hypertrophic prostate], Zeitschrift fur Urologie und Nephrologie, vol.61, pp.801-804, 1968. ,
Combination medical therapy for lower urinary tract symptoms and benign prostatic hyperplasia, Reviews in urology, vol.7, issue.8, pp.43-51, 2005. ,
The Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE Trial, European Urology, vol.54, issue.6, pp.1379-1384, 2008. ,
DOI : 10.1016/j.eururo.2007.11.026
BENIGN PROSTATIC HYPERPLASIA CELL LINE VIABILITY AND MODULATION OF JM-27 BY DOXAZOSIN AND IBUPROFEN, The Journal of Urology, vol.174, issue.1, pp.375-379, 2005. ,
DOI : 10.1097/01.ju.0000161598.24740.34
Celecoxib for Treatment of Nocturia Caused by Benign Prostatic Hyperplasia: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study, Urology, vol.72, issue.4, pp.813-816, 2008. ,
DOI : 10.1016/j.urology.2008.04.069
Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon. The Journal of steroid biochemistry and molecular biology, pp.233-239, 2002. ,
Serenoa repens (Permixon???): A 5?-reductase types I and II inhibitor?new evidence in a coculture model of BPH, The Prostate, vol.21, issue.4, pp.232-241, 1999. ,
DOI : 10.1002/(SICI)1097-0045(19990901)40:4<232::AID-PROS4>3.0.CO;2-0
Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. The Prostate, pp.77-83, 1998. ,
Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients, European urology, vol.21, issue.15, pp.309-314, 1992. ,
Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia. The Prostate, pp.259-266, 2000. ,
Effect of the Lipidosterolic Extract of Serenoa repens (Permixon<sup>®</sup>) and Its Major Components on Basic Fibroblast Growth Factor-Induced Proliferation of Cultures of Human Prostate Biopsies, European Urology, vol.33, issue.3, pp.340-347, 1998. ,
DOI : 10.1159/000019570
Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. The Journal of urology, pp.507-510, 2005. ,
Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon??) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils, Prostaglandins, Leukotrienes and Essential Fatty Acids, vol.57, issue.3, pp.299-304, 1997. ,
DOI : 10.1016/S0952-3278(97)90548-2
Effect of Serenoa repens, Lycopene, and Selenium on Proinflammatory Phenotype Activation: An In Vitro And In Vivo Comparison Study, Urology, vol.77, issue.1, pp.248-249, 2011. ,
DOI : 10.1016/j.urology.2010.07.514
BPH and Inflammation: Pharmacological Effects of Permixon on Histological and Molecular Inflammatory Markers. Results of a Double Blind Pilot Clinical Assay, European Urology, vol.44, issue.5, pp.549-555, 2003. ,
DOI : 10.1016/S0302-2838(03)00368-3
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proceedings of the National Academy of Sciences of the United States of America, pp.15545-15550, 2005. ,
Correlation between benign prostatic hyperplasia and inflammation, Current Opinion in Urology, vol.23, issue.1, pp.5-10, 2013. ,
DOI : 10.1097/MOU.0b013e32835abd4a
Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) European urology, pp.72-78, 2005. ,
Diclofenac for Treatment of Nocturia Caused by Nocturnal Polyuria: A Prospective, Randomised, Double-Blind, Placebo-Controlled Crossover Study, European Urology, vol.49, issue.4, pp.720-725, 2006. ,
DOI : 10.1016/j.eururo.2005.11.026
Effects of the lipido-sterolic extract of Serenoa repens (Permixon) on infiltrating cells and inflammatory markers in prostatic tissues from BPH patients Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate The Prostate, European urology, vol.62, issue.56, pp.171-182, 2002. ,
Evaluation of Interleukin-8 in Expressed Prostatic Secretion as a Reliable Biomarker of Inflammation in Benign Prostatic Hyperplasia, Urology, vol.74, issue.2, pp.340-344, 2009. ,
DOI : 10.1016/j.urology.2009.02.064
Biomarkers of Systemic Inflammation and Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial, American Journal of Epidemiology, vol.171, issue.5, pp.571-582, 2010. ,
DOI : 10.1093/aje/kwp406
Seminal Plasma Cytokines and Chemokines in Prostate Inflammation: Interleukin 8 as a Predictive Biomarker in Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Benign Prostatic Hyperplasia, European Urology, vol.51, issue.2, pp.524-533, 2007. ,
DOI : 10.1016/j.eururo.2006.07.016
Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas, European Journal of Cancer, vol.40, issue.9, pp.1418-1422, 2004. ,
DOI : 10.1016/j.ejca.2004.01.036
Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Molecular and cellular biology, pp.2373-2386, 2006. ,
PIK3CA and TFRC Located in 3q Are New Prognostic Factors in Esophageal Squamous Cell Carcinoma, Annals of Surgical Oncology, vol.94, issue.7, pp.961-966, 2006. ,
DOI : 10.1245/ASO.2006.08.006
, and invasive cervical cancer: identification of candidate genes in pathogenesis of invasion in cervical cancer, International Journal of Gynecological Cancer, vol.18, issue.5, pp.1051-1059, 2008. ,
DOI : 10.1111/j.1525-1438.2007.01164.x
Molecular Cancer Phenotype in Normal Prostate Tissue, European Urology, vol.55, issue.4, pp.885-890, 2009. ,
DOI : 10.1016/j.eururo.2008.04.105
A minimal connected network of transcription factors regulated in human tumors and its application to the quest for universal cancer biomarkers Role of HIF-1 and NFkappaB transcription factors in the modulation of transferrin receptor by inflammatory and anti-inflammatory signals. The Journal of biological chemistry, Immunological reviews 2012, pp.20674-20686, 2008. ,
The NF-kappaB/IL- 6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World journal of urology, pp.477-489, 2007. ,
Metallothioneins: unparalleled diversity in structures and functions for metal ion homeostasis and more, Natural Product Reports, vol.423, issue.Supplement 1, pp.720-741, 2010. ,
DOI : 10.1039/b906685n
Metallothionein and the biology of aging Ageing research reviews, pp.132-145, 2011. ,
Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat Pharmacological research : the official journal of the Italian Pharmacological Society A signaling network in phenylephrine-induced benign prostatic hyperplasia, Endocrinology, vol.34, issue.150, pp.171-179, 1996. ,
Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia, Proceedings of the National Academy of Sciences of the United States of America, pp.3755-3760, 2011. ,
DOI : 10.1073/pnas.1018086108
Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. The Prostate, pp.153-159, 2004. ,
Identifying differentially expressed genes using false discovery rate controlling procedures, Bioinformatics, vol.19, issue.3, pp.368-375, 2003. ,
DOI : 10.1093/bioinformatics/btf877
URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.319.4699